BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL

"Phase 1 dose escalation/decline (3+3) :~starting dose: 5×10\^5 cells/kg, According to effective expansion and clinical efficacy data, a descending dose escalation model will be adopted: such as 1×10\^5 cells/kg, 5×10\^4 cells/kg.~If the 5×10\^5 cells/kg dose group does not achieve efficient expansion and clinical benefit, an ascending dose escalation model will be adopted, such as 2×10\^6 cells/kg, 6×10\^6 cells/kg.~Phase 2 : dose of RP2D."

"Intravenous fludarabine 25\~30 mg/m\^2/day on days~-5, -4, and -3."

Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.